Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;21(1):18-30.
doi: 10.1007/s12094-018-1973-6. Epub 2018 Nov 15.

SEOM clinical guidelines in early stage breast cancer (2018)

F Ayala de la Peña  1 , R Andrés  2 , J A Garcia-Sáenz  3 , L Manso  4 , M Margelí  5 , E Dalmau  6 , S Pernas  7 , A Prat  8 , S Servitja  9 , E Ciruelos  10   11
Affiliations

SEOM clinical guidelines in early stage breast cancer (2018)

F Ayala de la Peña et al. Clin Transl Oncol. 2019 Jan.

Abstract

Breast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially curable stages. Nevertheless, around 20-30% of patients will relapse despite appropriate locoregional and systemic therapies. A better knowledge of this disease is improving our ability to select the most appropriate therapy for each patient with a recent diagnosis of an early stage breast cancer, minimizing unnecessary toxicities and improving long-term efficacy.

Keywords: Adjuvant; Early breast cancer; Follow-up; Genomic predictive test; Neoadjuvant.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

FAP reports grants from Roche and Celgene, other from Roche, Celgene, Eisai, AstraZeneca, Pfizer, Pierre Fabre and Novartis, outside the submitted work. RA has nothing to disclose. JAGS reports personal fees from Novartis and Celgene, grants from AstraZeneca, other from Roche, outside the submitted work. LM reports other from Roche, other from AstraZeneca, other from Novartis, other from Tesaro, outside the submitted work. MM has received speaker honoraria and funding for some independent medical education activities from Roche, Novartis, Astra Zeneca, Kern and Merck outside the submitted work. ED has nothing to disclose. SP reports personal fees and non-financial support from Roche, other from Polyphor, non-financial support from Pierre Fabre, outside the submitted work. AP reports personal fees from Nanostring, Roche, Amgen, Novartis, Eli Lilly and Pfizer, and grants from Roche, Novartis and Nanostring, all outside the submitted work. AP is part of the scientific advisory board of Oncolytics Biotech. SS has nothing to disclose. EC reports personal fees and other from Roche, Pfizer, Novartis, MSD, Celgene, Lilly and Pierre Fabre, outside the submitted work.

Ethical standards

The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study, no informed consent is required.

References

    1. SEOM: Las Cifras Del Cáncer En España. 2018. https://seom.org/seomcms/images/stories/recursos/Las_Cifras_del_cancer_e.... Accessed 15 Oct 2018.
    1. Cho S-H, Jeon J, Kim SI. Personalized medicine in breast cancer: a systematic review. J Breast Cancer. 2012;15:265–272. doi: 10.4048/jbc.2012.15.3.265. - DOI - PMC - PubMed
    1. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444. doi: 10.1016/S0140-6736(11)61625-5. - DOI - PMC - PubMed
    1. Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition–summary document. Ann Oncol. 2007;19:614–622. doi: 10.1093/annonc/mdm481. - DOI - PubMed
    1. Polley YC, Leung SCY, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. An International Ki67 Reproducibility Study. J Natl Cancer Inst. 2013;105:1897–1906. doi: 10.1093/jnci/djt306. - DOI - PMC - PubMed